Key Findings: ARNT Molecular Glue Degrader NEO-811 Commences Phase 1/2 First-in-Human Study for Unresectable Clear Cell Renal Cell Carcinoma Patients
An open-label, first-in-human (FiH), Phase 1/2 dose-escalation and expansion study (NEO-811-101) of NEO-811, an ARNT molecular glue degrader, has been initiated for patients with locally advanced or metastatic unresectable clear cell renal cell carcinoma (ccRCC). This study represents a crucial step in exploring the potential of this innovative molecular glue degrader modality to provide an effective therapeutic option for challenging cancer types like ccRCC, which have historically been difficult to treat.
Technical and Clinical Details: Mechanism of ARNT Molecular Glue Degrader and Study Design
NEO-811 is a molecular glue degrader that targets ARNT (Aryl Hydrocarbon Receptor Nuclear Translocator), a transcription factor. Molecular glues induce ubiquitination of a target protein (in this case, ARNT) by bringing two otherwise non-interacting proteins (ARNT and an E3 ubiquitin ligase) into close proximity, thereby promoting its degradation by the proteasome. ARNT is a critical transcription factor involved in hypoxia response and cancer cell proliferation and survival, playing an important role in ccRCC pathogenesis. Therefore, degrading ARNT represents a novel strategy to inhibit cancer cell growth and exert anti-tumor effects.
The NEO-811-101 study comprises two phases:
- Phase 1 (Dose Escalation): A small number of patients receive NEO-811 starting at low doses, with doses gradually increased to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD). The primary objective is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D).
- Phase 2 (Dose Expansion): NEO-811 is administered at the RP2D to a larger cohort of patients to evaluate preliminary efficacy signals.
In this study, NEO-811 will initially be evaluated as a monotherapy. This is a vital step to understand the standalone effect of a molecular glue degrader for a specific cancer type. The trial targets patients with advanced or metastatic unresectable clear cell renal cell carcinoma, who often show resistance to existing therapies.
Background and Industry Context: Unmet Medical Needs in Renal Cell Carcinoma and the Rise of Targeted Protein Degradation
Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinoma, and in its advanced stages, it carries a poor prognosis with high unmet medical needs. While existing targeted therapies and immunotherapies have brought advancements, many patients acquire treatment resistance, necessitating further therapeutic options. Targeted Protein Degradation (TPD), through modalities like PROTACs and molecular glues, is a novel drug discovery paradigm that exerts therapeutic effects by degrading specific proteins. TPD holds the potential to revolutionize cancer treatment by enabling approaches to ‘undruggable’ targets that are difficult to inhibit enzymatically. Research into molecular glue degraders like NEO-811 expands the diversity and potential of this TPD field.
Future Outlook: The Role of Molecular Glue Degraders in ccRCC Treatment
The progress of the NEO-811 Phase 1/2 study holds significant implications for establishing the role of molecular glue degraders in clear cell renal cell carcinoma treatment. If NEO-811 demonstrates a favorable safety profile and promising efficacy signals, it will be developed as a new therapeutic option for ccRCC patients, either as a monotherapy or as part of combination therapy. The future outlook involves transitioning to larger clinical trials based on the study results, to validate whether this innovative approach can improve patients’ quality of life and survival. Molecular glue degraders hold the potential to open new frontiers in precision medicine for cancer treatment.
Source: #
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments